Publications by authors named "Rongpei Gou"
Article Synopsis
- Selective pressure from the drug nirmatrelvir has led to the emergence of drug-resistant mutations in the SARS-CoV-2 M protein, particularly the L50F and E166V mutations, which complicate COVID-19 treatment.
- Previous research identified two novel nonpeptide inhibitors, NMI-001 and NMI-002, as alternatives that bind differently than nirmatrelvir and could combat drug resistance.
- A new compound, Z1557501297 (NMI-003), showed promising inhibitory effects against the resistant mutants E166V and L50F+E166V, suggesting it could be the basis for developing new antiviral treatments for resistant strains of SARS-CoV-2.
Central nervous system (CNS) drugs have had a significant impact on treating a wide range of neurodegenerative and psychiatric disorders. In recent years, deep learning-based generative models have shown great potential for accelerating drug discovery and improving efficacy. However, specific applications of these techniques in CNS drug discovery have not been widely reported.
View Article and Find Full Text PDFSolute carrier transporters (SLCs) are a class of important transmembrane proteins that are involved in the transportation of diverse solute ions and small molecules into cells. There are approximately 450 SLCs within the human body, and more than a quarter of them are emerging as attractive therapeutic targets for multiple complex diseases, e.g.
View Article and Find Full Text PDFHuman dopamine transporter (hDAT) regulates the reuptake of extracellular dopamine (DA) and is an essential therapeutic target for central nervous system (CNS) diseases. The allosteric modulation of hDAT has been identified for decades. However, the molecular mechanism underlying the transportation is still elusive, which hinders the rational design of allosteric modulators against hDAT.
View Article and Find Full Text PDF